Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) have earned an average rating of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.00.
Several analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. SunTrust Banks reiterated a “hold” rating and set a $4.00 target price on shares of Oncomed Pharmaceuticals in a research report on Friday, October 6th. Jefferies Group reiterated a “buy” rating and set a $5.00 target price on shares of Oncomed Pharmaceuticals in a research report on Thursday, September 28th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $6.00 target price on shares of Oncomed Pharmaceuticals in a research report on Tuesday, September 19th.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) opened at $3.89 on Friday. Oncomed Pharmaceuticals has a 12-month low of $2.91 and a 12-month high of $10.89.
A number of large investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new position in Oncomed Pharmaceuticals in the third quarter valued at about $4,693,000. Vanguard Group Inc. boosted its position in Oncomed Pharmaceuticals by 5.3% in the second quarter. Vanguard Group Inc. now owns 995,646 shares of the biopharmaceutical company’s stock valued at $3,315,000 after buying an additional 50,161 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Oncomed Pharmaceuticals by 42.1% in the second quarter. Ameriprise Financial Inc. now owns 966,995 shares of the biopharmaceutical company’s stock valued at $3,221,000 after buying an additional 286,545 shares in the last quarter. Cannell Peter B & Co. Inc. boosted its position in Oncomed Pharmaceuticals by 23.1% in the second quarter. Cannell Peter B & Co. Inc. now owns 407,741 shares of the biopharmaceutical company’s stock valued at $1,358,000 after buying an additional 76,445 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its position in Oncomed Pharmaceuticals by 72.9% in the third quarter. Candriam Luxembourg S.C.A. now owns 370,000 shares of the biopharmaceutical company’s stock valued at $1,672,000 after buying an additional 156,000 shares in the last quarter. Hedge funds and other institutional investors own 39.44% of the company’s stock.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.